Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases
Objective: To evaluate the efficacy of the anti-TNFa (Tumor Necrosis Factor alpha) drugs in a variety of pathologic conditions such as psoriatic arthritis, undifferentiated entheso-arthritides, chronic inflammatory bowel diseases, adult onset Still's disease, Behcet disease. Methods: Review of...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
PAGEPress Publications,
2011-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective: To evaluate the efficacy of the anti-TNFa (Tumor Necrosis Factor alpha) drugs in a variety of pathologic conditions such as psoriatic arthritis, undifferentiated entheso-arthritides, chronic inflammatory bowel diseases, adult onset Still's disease, Behcet disease. Methods: Review of all published studies evaluating the efficacy of these drugs (mainly infliximab and etanercept, adalimumab to a lesser degree) on the above diseases. Results: Results are reported for each pathologic condition. Both drugs showed to be very efficacious in all the above conditions, except Crohn disease where etanercept does not seem adequate. Conclusions: Both drugs work extremely well, even though comparison between infliximab and etanercept efficacy cannot be performed, due to the lack of a direct comparison. |
|---|---|
| Item Description: | 10.4081/reumatismo.2005.4s.22 0048-7449 2240-2683 |